Consensus Cellectar Biosciences, Inc.

Stocks

CLRB

US15117F8804

Pharmaceuticals

Market Closed - 16:00:00 2026-10-23 EDT 5-day change 1st Jan Change
1.220 USD +4.27% Intraday chart for Cellectar Biosciences, Inc. +7.02% -58.64%

Evolution of the Average Target: Cellectar Biosciences, Inc.

Evolution of the Average Target - Cellectar Biosciences, Inc.

Evolution of the Target Price: Cellectar Biosciences, Inc.

Evolution of the Target Price - Cellectar Biosciences, Inc.

Changes in Analyst Recommendations: Cellectar Biosciences, Inc.

154c94.BV1HRePSZrkukktt6we3AlamrKJO_PfMcJ4uDXr0ToU.bTk1KLeaCe9W4CIorFeFaCPn59cancWFO6ZdSyLGfekwBxA_tIQgwxqmOA~033ac759c0e77e6a8d21eb9559fd8ef7
25-10-27 Cellectar Says FDA Grants Rare Pediatric Drug Designation for Iopofosine in High-Grade Glioma MT
25-10-27 Cellectar Biosciences, Inc. Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma CI
25-10-06 Cellectar wins EMA nod to seek conditional approval for iopofosine in rare blood cancer RE
25-10-06 Cellectar Biosciences Announces Iopofosine I 131 as A Treatment for Refractory (Post-Btki) Waldenstrom Macroglobulinemia (Wm) CI
24-11-19 Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $14, Maintains Outperform Rating MT
24-03-28 Roth MKM Raises Cellectar Biosciences' Price Target to $28 From $20, Retains Buy Rating MT
24-03-28 Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $11, Maintains Outperform Rating MT
24-01-09 Oppenheimer Boosts Price Target on Cellectar Biosciences to $11 From $8, Maintains Outperform Rating MT
23-09-11 Oppenheimer Cuts Cellectar Biosciences Price Target to $8 From $10, Maintains Outperform Rating MT
23-05-05 Oppenheimer Adjusts Cellectar Biosciences Price Target to $10 From $11, Maintains Outperform Rating MT
22-11-04 HC Wainwright Adjusts Price Target on Cellectar Biosciences to $4 From $30, Maintains Buy Rating MT
22-11-04 Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $47, Maintains Outperform Rating MT
22-08-08 Oppenheimer Adjusts Cellectar Biosciences Price Target to $47 From $5.50, Maintains Outperform Rating MT
22-02-02 Maxim Group Adjusts Cellectar Biosciences Price Target to $2 From $3, Maintains Buy Rating MT
20-12-28 Cellectar Biosciences : Oppenheimer Adjusts Cellectar Biosciences' Price Target to $5.50 From $5, Maintains Outperform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+842.62%
+4.56%
+5.91%
-0.3%
-1.16%
+9.97%
-3.36%
+22.49%
-9.55%
+2.66%
Average +87.39%
Weighted average by Cap. +3.79%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.220USD
Average target price
11.50USD
Spread / Average Target
+842.62%
High Price Target
15.00USD
Spread / Highest target
+1,129.51%
Low Price Target
10.00USD
Spread / Lowest Target
+719.67%

Analyst Consensus Detail

Analyst consensus - Cellectar Biosciences, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Cellectar Biosciences, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cellectar Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. CLRB Stock
  4. Consensus Cellectar Biosciences, Inc.